Deutsche Bank AG Lowers Holdings in Organon & Co. $OGN

Key Points

• Deutsche Bank AG has reduced its stake in Organon & Co. by 44.6% in Q1, bringing its holdings to 70,913 shares valued at approximately $1.06 million.
• Organon & Co.'s latest financial results showed an earnings per share (EPS) of $1.00, surpassing analysts' expectations and reflecting a revenue of $1.59 billion for the quarter.
• Institutional investors currently own 77.43% of Organon & Co.'s stock, indicating significant institutional interest in the company.

Deutsche Bank AG lessened its position in shares of Organon & Co. (NYSE:OGN - Free Report) by 44.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 70,913 shares of the company's stock after selling 57,179 shares during the period. Deutsche Bank AG's holdings in Organon & Co. were worth $1,056,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in OGN. Massachusetts Financial Services Co. MA lifted its position in shares of Organon & Co. by 8.3% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 10,715,445 shares of the company's stock valued at $159,553,000 after buying an additional 820,378 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Organon & Co. during the 4th quarter valued at $11,892,000. Dimensional Fund Advisors LP lifted its position in shares of Organon & Co. by 23.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,284,408 shares of the company's stock valued at $48,999,000 after buying an additional 629,191 shares during the last quarter. Siemens Fonds Invest GmbH purchased a new position in shares of Organon & Co. during the 4th quarter valued at $8,998,000. Finally, Cerity Partners LLC lifted its position in shares of Organon & Co. by 77.1% during the 1st quarter. Cerity Partners LLC now owns 1,153,044 shares of the company's stock valued at $17,169,000 after buying an additional 501,959 shares during the last quarter. Hedge funds and other institutional investors own 77.43% of the company's stock.

Organon & Co. Trading Up 2.3%

OGN traded up $0.22 on Friday, hitting $9.40. 4,579,414 shares of the company were exchanged, compared to its average volume of 4,767,843. The firm has a fifty day simple moving average of $9.61 and a two-hundred day simple moving average of $11.23. The company has a debt-to-equity ratio of 11.98, a quick ratio of 1.13 and a current ratio of 1.65. Organon & Co. has a 12 month low of $8.01 and a 12 month high of $22.67. The stock has a market capitalization of $2.44 billion, a PE ratio of 3.49, a price-to-earnings-growth ratio of 0.86 and a beta of 0.60.

Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.06. The business had revenue of $1.59 billion during the quarter, compared to analysts' expectations of $1.55 billion. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The business's revenue was down .8% on a year-over-year basis. During the same quarter last year, the business posted $1.12 EPS. Organon & Co. has set its FY 2025 guidance at EPS. Sell-side analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 11th. Shareholders of record on Friday, August 15th will be issued a $0.02 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.9%. Organon & Co.'s dividend payout ratio (DPR) is presently 2.97%.

Wall Street Analyst Weigh In

OGN has been the topic of a number of recent research reports. Piper Sandler dropped their price target on Organon & Co. from $24.00 to $18.00 and set an "overweight" rating on the stock in a research report on Thursday, May 15th. Evercore ISI cut Organon & Co. from an "outperform" rating to an "inline" rating in a report on Friday, May 2nd. BNP Paribas raised Organon & Co. to a "strong-buy" rating in a report on Thursday, May 22nd. Finally, Morgan Stanley dropped their price objective on Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $18.00.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.